Please provide your email address to receive an email when new articles are posted on . The FDA has advised health care professionals that they should not use unapproved epinephrine nasal solutions ...
A recall has been issued for nasal solution products used in hospitals because of the potential for errors in administering the drug. Endo Inc. announced on Dec. 20 that one of its operating ...
Epinephrine nasal solutions from BPI Labs and Endo USA should not be used, according to the FDA. Similarities between the packaging for certain intranasal and intravenous epinephrine products may ...
Zacks Small Cap Research on MSN
NSRX: Initiating coverage – sniffing out a better solution
By John Vandermosten, CFA NYSE:NSRX READ THE FULL NSRX INITIATION RESEARCH REPORT We are initiating coverage of Nasus Pharma Ltd. (NYSE:NSRX) with a valuation of $19.00 per share. This value is based ...
The company is voluntarily recalling all lots of Adrenalin Chloride Solution (EPINEPHrine nasal solution, USP) 30 mg/30 mL (1 mg/mL) 30 mL vials due to misleading labeling and its status as an ...
Endo, Inc (OTCQX: NDOI) (“Endo”), announced today that one of its operating subsidiaries, Endo USA, Inc., is voluntarily recalling all lots within expiry of Adrenalin® Chloride Solution (EPINEPHrine ...
Presented at Respiratory Drug Delivery 2024, the Nasdepi Canine Study Indicates the Dry Powder Nasal Solution Provides a Faster and More Effective Treatment for Anaphylaxis as a Result of Severe ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results